Agentic AI is coming to change Drug Discovery in Life Sciences

The Next Shift in Pharmaceutical R&D Is Not About Better Search. It Is About AI That Acts.

Over 50% of the world’s leading pharmaceutical companies choose Sinequa.

The first wave of AI in pharmaceutical R&D improved how researchers find information. Cognitive search replaced keyword queries with semantic understanding. Unified search interfaces replaced system-by-system lookups. The result was faster access to scientific knowledge across ELNs, LIMS, compound databases, and literature.

The next wave goes further. Agentic AI does not just surface information when a researcher asks for it. It autonomously monitors data streams, identifies patterns across disparate sources, triggers workflows, generates hypotheses, and executes multi-step research tasks on behalf of the scientists directing it.

For pharmaceutical R&D organizations, this shift has specific and significant implications: for how early research is conducted, how decisions are made, how workflows are structured, and how competitive advantage is built in an industry where time-to-market directly determines therapeutic and commercial outcomes.

This whitepaper covers what agentic AI means specifically for drug discovery and development, where the highest-value early use cases are, and what infrastructure is required to deploy AI agents responsibly in a regulated pharmaceutical environment.

What You Will Learn

• How agentic AI differs from AI-powered search and why that distinction matters for pharmaceutical R&D strategy
• Where the highest-value agentic AI use cases in drug discovery are today and which are on the near-term horizon
• What infrastructure requirements separate a pharma organization that is ready to deploy AI agents from one that is not
• How the leading pharmaceutical organizations are positioning themselves for the agentic AI shift now, before it becomes table stakes

Who This Whitepaper Is For

This resource is written for senior life sciences leaders who are moving beyond the question of whether to invest in AI and are now asking what the agentic AI shift means for their organization specifically:

• Chief Scientific Officers and Chief R&D Officers assessing the strategic implications of agentic AI for research productivity, competitive positioning, and pipeline velocity
• Heads of Digital R&D and R&D Informatics responsible for the technical architecture that will support AI agent deployment in scientific workflows
• Innovation leaders in pharma building the internal case for agentic AI investment and evaluating which use cases to prioritize in a 12 to 24 month horizon
• IT and platform leaders assessing the infrastructure requirements for deploying AI agents in regulated, IP-sensitive pharmaceutical environments

What Is Agentic AI and Why Does It Matter for Drug Discovery?

Agentic AI refers to AI systems that do not simply respond to queries but act autonomously to complete multi-step tasks, pursue defined objectives, and adapt their behavior based on intermediate results. An AI agent in a drug discovery context does not wait for a researcher to ask a question. It monitors data sources, identifies relevant signals, initiates workflows, retrieves and synthesizes information from connected systems, generates candidate outputs, and escalates decisions to human researchers when required.

This is a materially different capability from AI-powered search, even sophisticated cognitive search. Search, by definition, is initiated by a human query. The researcher asks a question; the system retrieves and ranks results. Agentic AI reverses that dynamic: the system monitors for conditions and acts on them, surfacing insights before a researcher has formulated the query, and executing tasks that currently require human initiation at every step.

For pharmaceutical R&D, the implications of this reversal are specific and substantial. Drug discovery involves monitoring vast amounts of continuously updating information: new literature publications, evolving patent landscapes, competitor pipeline developments, emerging safety signals, regulatory guidance updates, and internal experimental results. Much of this monitoring is currently done manually, episodically, and incompletely. Agentic AI systems can monitor these streams continuously, extract relevant signals, and deliver structured intelligence to research teams as a matter of course rather than as the result of a dedicated search effort.

The shift from reactive search to proactive AI agency is not a marginal efficiency improvement. It changes what is possible in early-stage research: not just faster access to known information, but systematic discovery of connections and patterns that manual monitoring would miss entirely.

Where Agentic AI Creates the Highest Value in Pharmaceutical R&D

The use cases for agentic AI in drug discovery span the full research lifecycle, but several stand out as particularly high-value in the near term because they combine high manual effort today with well-defined success criteria that AI agents can be directed toward.

• Continuous literature and competitive intelligence monitoring. Research teams need to stay current on a rapidly expanding scientific literature, competitive pipeline activity, and regulatory guidance. Today this monitoring is done through periodic manual searches, alerting services with limited semantic awareness, and information shared informally across teams. An AI agent configured to monitor PubMed, patent databases, clinical trial registries, and regulatory agency publications continuously, and to deliver structured summaries of relevant developments to defined research audiences, eliminates a significant manual overhead while improving coverage and timeliness.
• Automated hypothesis generation from internal and external data. Target identification and validation require synthesizing information from across internal experimental data, published biology, genetic databases, and disease pathway knowledge. AI agents that can traverse these sources autonomously, identify statistical co-occurrences and biological relationships, and generate ranked hypotheses for researcher review compress the exploration phase of early-stage research substantially. The researcher’s role shifts from conducting the synthesis to evaluating and directing the agent’s outputs.
• SAR and ADMET analysis acceleration. Structure-activity relationship analysis and ADMET profiling during lead optimization involve retrieving prior experimental data for related compound series, identifying patterns in assay results, and flagging liability signals. These are time-intensive tasks with well-defined inputs and outputs, making them strong candidates for AI agent automation. An agent configured with access to internal compound databases, prior assay repositories, and published ADMET literature can execute preliminary analysis autonomously and deliver structured outputs for chemist review.
• Regulatory intelligence and submission preparation. Regulatory submissions require locating prior agency correspondence, identifying precedent language from analogous submissions, cross-referencing safety data across programs, and assembling supporting documentation. AI agents configured with access to the regulatory submission archive and prior agency interaction history can automate the retrieval and preliminary assembly components of this work, freeing regulatory scientists for the judgment-intensive tasks that require human expertise.

What Infrastructure Agentic AI Requires in a Pharmaceutical Environment

Deploying AI agents in pharmaceutical R&D is not simply a matter of connecting a large language model to scientific databases. The infrastructure requirements that determine whether an agentic AI deployment succeeds or fails in a regulated, IP-sensitive environment are specific and demanding.

• High-quality, unified retrieval. AI agents are only as useful as the information they can access and the accuracy with which they can retrieve it. An agent that generates hypotheses or summaries based on incomplete retrieval, or that misses relevant prior findings because its search infrastructure lacks the semantic depth to surface them, produces outputs that mislead rather than inform. The retrieval layer beneath any agentic AI deployment in pharma must be enterprise-grade: connecting all relevant scientific data sources, handling scientific data types natively, and applying semantic understanding tuned to pharmaceutical and biomedical vocabulary.
• Access control enforcement at the retrieval layer. In pharmaceutical organizations, scientific data carries IP sensitivity, export control obligations, and program-level access restrictions. An AI agent operating on behalf of a researcher must not access data that researcher is not authorized to see. This requires access controls applied at the retrieval stage, before any content enters the agent’s reasoning pipeline, not as a post-processing filter that can be circumvented. Early-binding security is the architectural requirement, not a configuration option.
• Explainability and audit trails. Regulatory environments require that decisions be traceable to their evidentiary basis. When an AI agent contributes to a research decision, a go/no-go judgment, or a regulatory submission, the basis for its contribution must be documentable. Agentic AI deployments in pharma require logging of agent actions, source attribution for agent-generated outputs, and human review checkpoints at defined decision stages.
• Human-in-the-loop governance. AI agents in pharmaceutical R&D are not fully autonomous decision-makers. They are productivity and intelligence infrastructure that operates under human scientific direction. The governance model must define clearly which decisions agents can execute autonomously, which require researcher review before action, and which require senior scientific or regulatory approval. Organizations that attempt to deploy fully autonomous agents without this governance layer typically encounter compliance barriers or generate outputs that require more remediation than the automation saved.